|
|
Post by babaoriley on Jun 21, 2017 17:25:05 GMT -5
Could there be a deal contingent on an IRS determination that the acquiring company can utilize MNKD's massive NOL? If you were a buyer of MNKD, you'd surely want to know that, if it were a close question. If there's no chance to use it, doesn't mean no one would want MNKD, but look at how a deal where the NOL is available would sound to the Board and shareholders of an acquiring company?
|
|
|
|
Post by falconquest on Jun 21, 2017 18:04:27 GMT -5
My response to the original question posed by Kastanes can be found in one of my posts that was titled "Once a CEO, always a CEO which Matt (poster, not former CEO) eluded to. Mike put himself in a prime position if Mannkind tanks. I have yet to see him accomplish anything that helps the company near term. Ok so we're sponsoring a reality TV show, we have our own sales force instead of a contract sales force, we have a DTC commercial coming out soon and have an agreement for Afrezza in Brazil. That's a lot of "stuff" but does any of it really help us short term? The answer to our problems (which I have repeated ad nauseum) is, we need to sell the product!
|
|
|
|
Post by cjc04 on Jun 21, 2017 18:23:04 GMT -5
Could there be a deal contingent on an IRS determination that the acquiring company can utilize MNKD's massive NOL? If you were a buyer of MNKD, you'd surely want to know that, if it were a close question. If there's no chance to use it, doesn't mean no one would want MNKD, but look at how a deal where the NOL is available would sound to the Board and shareholders of an acquiring company? 1. Reverse Morris Trust.... very complicated, and I can't imagine a company that is properly set up for that. 2. A buy IN..... say MNKD prints another 90 million shares and sells them at the current price, or even higher $2.50/sh to the merging company giving them 45% ownership (why would a company pay this? To basically take control of the company and preserve the $2b in nol's) and giving MNKD $140 - $240 million to operate... AND give MNKD a loan for how ever many hundred million $ they see fit stuffing MNKD with $400 - $500 mil to make everything work. I have no idea what I'm talking about, but #2 seems like an easy way for a company who believes it can make Afrezza work to take a controlling stake, stuff it with cash, and preserve the NOL's. |
|
|
|
Post by sayhey24 on Jun 21, 2017 18:55:06 GMT -5
Let me be clear, no matter how I might characterize Mike's personality, he may be just what the doctor ordered. In a year or so, I want to be able to call him a brilliant visionary! "the viscous world of Big Pharma" - cjc, LOL, my kind of malaprop or malaspell. And make no mistake, Big Pharma is, indeed, a tacky, gelatinous, mucousy world!  I mean nothing against Mike, I'm impressed with everything I've heard so far.... I'm really pointing out how absolutely dire and desperate the situation is for the company if Matt's departure and Mike's appointment is as we're being led to believe.... As for viscous,,,,, I knew a Sanofi rep and I couldn't believe what he was saying about Afrezza in the summer of 2015, while they were selling it. All I could picture was what EVERY insulin rep had to say in every endo office about Afrezza, true or not..... MNKD, alone, has no chance in that world. So what did your Sanofi rep friend say about afrezza? With many top diabetes advocates like Edelman and Bode and Hoskins and even Schiener all saying great things now about afrezza is your friend feeling stupid? As Edelman said it usually takes years for a new drugs potential to be understood. One thing I can say about your friend is they did not do a good job. My guess is they were too busy pushing Toujeo and that has not worked out very well. |
|
|
|
Post by brentie on Jun 21, 2017 19:44:31 GMT -5
Kastanes. Castagna. Hmmm. If I were Mike and wanted to post I wouldn't use my real name. I'd change it up a little bit. Hmmm. You uncloaked me! Twins!   |
|
|
|
Post by goyocafe on Jun 21, 2017 19:53:25 GMT -5
I mean nothing against Mike, I'm impressed with everything I've heard so far.... I'm really pointing out how absolutely dire and desperate the situation is for the company if Matt's departure and Mike's appointment is as we're being led to believe.... As for viscous,,,,, I knew a Sanofi rep and I couldn't believe what he was saying about Afrezza in the summer of 2015, while they were selling it. All I could picture was what EVERY insulin rep had to say in every endo office about Afrezza, true or not..... MNKD, alone, has no chance in that world. So what did your Sanofi rep friend say about afrezza? With many top diabetes advocates like Edelman and Bode and Hoskins and even Schiener all saying great things now about afrezza is your friend feeling stupid? As Edelman said it usually takes years for a new drugs potential to be understood. One thing I can say about your friend is they did not do a good job. My guess is they were too busy pushing Toujeo and that has not worked out very well. Wouldn't a buy in also deny shorts any chance of covering with a public offering? That seems like just deserve. |
|
|
|
Post by kuka on Jun 21, 2017 20:05:28 GMT -5
any company who buys MNKD now can get 50% of their purchase price refunded thru the short squeeze ... same thing Volkswagon did...google it
|
|
|
|
Post by brotherm1 on Jun 21, 2017 21:32:53 GMT -5
any company who buys MNKD now can get 50% of their purchase price refunded thru the short squeeze ... same thing Volkswagon did...google it How about you Google it and provide the link. You already sent me on a wild goose chase when you said to locate where the Mann Foundation bought 5 million more shares of MNKD after selling EYES stock. You still have not provided proof of that. Show me you're more than hot air |
|
|
|
Post by cjc04 on Jun 21, 2017 22:11:30 GMT -5
I mean nothing against Mike, I'm impressed with everything I've heard so far.... I'm really pointing out how absolutely dire and desperate the situation is for the company if Matt's departure and Mike's appointment is as we're being led to believe.... As for viscous,,,,, I knew a Sanofi rep and I couldn't believe what he was saying about Afrezza in the summer of 2015, while they were selling it. All I could picture was what EVERY insulin rep had to say in every endo office about Afrezza, true or not..... MNKD, alone, has no chance in that world. So what did your Sanofi rep friend say about afrezza? With many top diabetes advocates like Edelman and Bode and Hoskins and even Schiener all saying great things now about afrezza is your friend feeling stupid? As Edelman said it usually takes years for a new drugs potential to be understood. One thing I can say about your friend is they did not do a good job. My guess is they were too busy pushing Toujeo and that has not worked out very well. Never said he was a friend, he definitely was not... This was 6 or 8 months in and he was still clueless about how Afrezza even worked. Totally dismissed it and said it'd be dropped. as I attempted to enlighten him on the drug that was going to revolutionize diabetes, he laughed and asked how MNKD's stock price was doing.... From then to now, I am the one feeling pretty stupid. |
|
|
|
Post by gamblerjag on Jun 21, 2017 22:44:42 GMT -5
Brothern.. sorry you wasted your time.. I personally would dismiss some peoples continued incorrect claims. Some just try to hard to convince... motive???
|
|
|
|
Post by mnkdfann on Jun 21, 2017 23:25:41 GMT -5
any company who buys MNKD now can get 50% of their purchase price refunded thru the short squeeze ... same thing Volkswagon did...google it How about you Google it and provide the link. You already sent me on a wild goose chase when you said to locate where the Mann Foundation bought 5 million more shares of MNKD after selling EYES stock. You still have not provided proof of that. Show me you're more than hot air There WAS a famous short squeeze involving Volkswagen in 2008, but that was because Porsche made a takeover play. Porsche and its executives later faced lawsuits for market manipulation (afaik they were acquitted, but it was a long battle). Porsche actually lost the takeover attempt, though the two companies later merged in 2012. The financial press described it as Volkswagen swallowing Porsche, but that may not be completely accurate I'm not 100% sure. But that whole scenario was so far from Mannkind's current situation, that any comparison is ludicrous. It would be like Sanofi coming back to make a takeover attempt, then being taken over by Mannkind or merging as 50/50 partners. |
|
|
|
Post by slugworth008 on Jun 21, 2017 23:52:39 GMT -5
My response to the original question posed by Kastanes can be found in one of my posts that was titled "Once a CEO, always a CEO which Matt (poster, not former CEO) eluded to. Mike put himself in a prime position if Mannkind tanks. I have yet to see him accomplish anything that helps the company near term. Ok so we're sponsoring a reality TV show, we have our own sales force instead of a contract sales force, we have a DTC commercial coming out soon and have an agreement for Afrezza in Brazil. That's a lot of "stuff" but does any of it really help us short term? The answer to our problems (which I have repeated ad nauseum) is, we need to sell the product! Which translates to "cash" which is what we need the most. Hence selling product is paramount. |
|
|
|
Post by sportsrancho on Jun 22, 2017 5:43:02 GMT -5
So what did your Sanofi rep friend say about afrezza? With many top diabetes advocates like Edelman and Bode and Hoskins and even Schiener all saying great things now about afrezza is your friend feeling stupid? As Edelman said it usually takes years for a new drugs potential to be understood. One thing I can say about your friend is they did not do a good job. My guess is they were too busy pushing Toujeo and that has not worked out very well. Never said he was a friend, he definitely was not... This was 6 or 8 months in and he was still clueless about how Afrezza even worked. Totally dismissed it and said it'd be dropped. as I attempted to enlighten him on the drug that was going to revolutionize diabetes, he laughed and asked how MNKD's stock price was doing.... From then to now, I am the one feeling pretty stupid. That's probably the mind set they all went in with... Now at least we have reps who feel the opposite! They get up in the morning happy to change lives, knowing that this is the best drug they have ever sold. Drive for hours, fight for insurance. And are proud to be a part of the MNKD team:-) I guess it's in the training they have been given and only having one drug to sell. And really understand Afrezza! |
|
|
|
Post by matt on Jun 22, 2017 6:11:40 GMT -5
Could there be a deal contingent on an IRS determination that the acquiring company can utilize MNKD's massive NOL? If you were a buyer of MNKD, you'd surely want to know that, if it were a close question. If there's no chance to use it, doesn't mean no one would want MNKD, but look at how a deal where the NOL is available would sound to the Board and shareholders of an acquiring company? Allowing an acquirer to use the NOL used to be permitted, but not since the early 1980's due to perceived abuses. There were several railroads that suddenly became industrial or consumer conglomerates on the backs of the railroad losses. Along came Section 382 of the tax code and the end of that strategy. Some NOL does carry over, but typically the value is only 1-2% of what it was. The exception is when the company is acquired in a Type G reorganization which is a special type of merger permitted with a bankrupt company. The details are complex if you don't know the reorg rules, but because the company must first be in bankruptcy it benefits the creditors more than the shareholders. Dendreon had more than $2 billion in losses, and Valeant bought all the tax assets with a present value of around $800 million for $15 million. |
|
|
|
Post by hellodolly on Jun 22, 2017 6:52:53 GMT -5
What is the point of this thread? Let me rewrite and take some literary license, as well:
"Sometimes an individual with a huge ego feels as though he/she can do anything, certainly including composing useless threads (you, know, like taking something and using it to sound intelligent). When such a thread becomes relevant, (irrespective of how much of it was actually due to the individual), the individual is celebrated as great, innovative, brilliant, a visionary, etc. When such a thread fails (again, irrespective of how much of it was actually due to the individual), the individual is not celebrated, is criticized by most and then some, lauded by others for taking on such a challenge, but, more importantly, rather quickly forgotten."
See any similarities?
Hello, Dolly, we all have our styles, and I try my best not to hide mine!! Not a knock on you baba...sarcasm about the initial post and stealing your comment to "sound intelligent" which by your thread impressed me. |
|
/production/original_573352236.gif)
